68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
about
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesNon-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and managementPET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literaturePulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsCurrent knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursHigh management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumoursPeptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imagingRole of positron emission tomography-computed tomography in bronchial mucoepidermoid carcinomas: a case series and review of the literature.Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.Feasibility of imaging esophageal cancer with labeled somatostatin analogueChallenges in nuclear medicine: innovative theranostic tools for personalized medicineSomatostatin receptor based imaging and radionuclide therapy.Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma.Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumorsPancreatic Neuroendocrine Tumors: an Update.Cardiothoracic manifestations of neuroendocrine tumours.Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.Update on nuclear medicine imaging of neuroendocrine tumors.Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrEndocrine tumors: the evolving role of positron emission tomography in diagnosis and management.Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumorsNordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.Surgery for carcinoid heart disease: current outcomes, concerns and controversies.A new dimension of FDG-PET interpretation: assessment of tumor biology.Non-FDG PET in oncology.Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.Imaging with non-FDG PET tracers: outlook for current clinical applications.Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.Feasibility and availability of ⁶⁸Ga-labelled peptides.⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.Role of PET/CT in the functional imaging of endocrine pancreatic tumors.Merkel cell carcinoma: what do we know about it and what should we do?Radionuclide therapy beyond radioiodine.Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.
P2860
Q24603675-1FFF90AC-F7A3-4D0F-AFD9-A1E1583E994CQ26795597-7F70E24B-E134-4687-BE18-219B5A1C5AA9Q26992201-74379A8E-5829-414F-857E-AC8567F75156Q26996521-D39D786C-6A96-4C53-B286-1C99DE93D40CQ28071483-B3C83691-59CC-42B9-8231-092A49BD3453Q28260008-4AFCCD76-0ACF-4748-80AF-371DD56085ADQ33397018-A1DE1666-5033-40CE-906D-81D9B1C297B2Q33611575-79C67F61-1AD1-4FCF-B7BC-F6D1110E712CQ34114196-0CE1BD3D-B84C-4A51-89FD-0F9B1E493A64Q34157385-49CC6CA2-214A-4511-9F54-7CA0688C8CF5Q34248487-BD0B81FD-CC92-41B2-A404-FCB6330A83CAQ34477028-4D06EB19-FB8F-418A-9EEA-320DB47E7EFEQ35049485-DCAC88EE-DF51-4C7D-9E76-59A524B56293Q35104505-8529FAD1-1C0F-45A2-8F2C-FBE13376BA66Q35296661-E5D68D93-9714-4388-B273-3A9305BDC1F4Q35724965-C9D657B3-D995-41B1-A5D8-CB22E46EAFB1Q36322884-FBF040EC-3DE8-4C85-9469-160C3FF15198Q36400062-D90D4183-607B-47E5-A374-EAEE801EA347Q36839240-29CEB1A9-D6F0-442E-AF96-268FA4E7CF12Q37026964-D5E50B5B-1CDF-4C0D-80AE-146C386ADEF7Q37063180-CD133E3D-9399-4361-9419-D195BB1B79DEQ37401346-A1DE2C81-9643-44DF-9C62-FB6B2F1471D2Q37425156-388899C3-BEED-4545-B010-F29EC519C303Q37612715-744BEFF4-EFCA-4320-9985-8B68839CCEF6Q37694773-34CB7BAD-010F-4155-9358-A9F12B80B535Q37765569-07F1F6F2-1FE6-4251-896A-686CA37EE958Q37798810-4EA3660C-3BE9-4113-B371-1FB1B13F2B49Q37827752-F05E934D-3A4F-4DE0-847F-4707B73B7A9DQ37956045-218F25F4-B854-419A-824E-0B7EFFC9D717Q37962416-5706E721-3E5E-4DAA-8630-53CFAA96DD4DQ37975101-904C8DE0-AEFD-488D-B3B0-0FB56292C69DQ37977337-DE0FA90F-245E-44CC-8B8D-E8060E75D6C3Q37986065-1BF1DF88-831D-4685-B565-32CB885FCF86Q37986605-F1B95FA1-20A3-41D9-8612-C372043F1DFAQ37990396-EFD116FE-64A6-4975-A9E9-9C932C7F70E7Q37990397-517B8B92-993A-482B-B9D0-1F786482F9F0Q37994083-45649DF5-872E-4B68-8D22-C664391FA46EQ38013521-FBE896A5-1C88-4A15-BED3-6593F1C6376AQ38027798-7BC6E6CF-0149-4A1D-B2BC-2AAFD8F0F756Q38036127-D743A0C8-3281-424D-B671-902D9913F7DD
P2860
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
description
im April 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2007
@uk
name
68Ga-DOTA-Tyr3-Octreotide PET ...... n Receptor Scintigraphy and CT
@en
68Ga-DOTA-Tyr3-Octreotide PET ...... n Receptor Scintigraphy and CT
@nl
type
label
68Ga-DOTA-Tyr3-Octreotide PET ...... n Receptor Scintigraphy and CT
@en
68Ga-DOTA-Tyr3-Octreotide PET ...... n Receptor Scintigraphy and CT
@nl
prefLabel
68Ga-DOTA-Tyr3-Octreotide PET ...... n Receptor Scintigraphy and CT
@en
68Ga-DOTA-Tyr3-Octreotide PET ...... n Receptor Scintigraphy and CT
@nl
P2093
P50
P1476
68Ga-DOTA-Tyr3-octreotide PET ...... n receptor scintigraphy and CT
@en
P2093
Christian Uprimny
Dirk Heute
Dorota Kendler
Georg Dobrozemsky
Irene J Virgolini
Michael Gabriel
Peter Kovacs
P304
P356
10.2967/JNUMED.106.035667
P407
P577
2007-04-01T00:00:00Z